Journals / Adnan Menderes Üniversitesi Tıp Fakültesi Dergisi / 2011 / Cilt: 12 - Sayı: 3

A rare cause of non-cirrhotic portal hypertension: Primary antiphospholipid syndrome

Non-sirotik portal hipertansiyonun nadir bir nedeni: Primer antifosfolipid sendromu

Pages
41–43
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Herein we present a case of non-cirrhotic portal hypertension associated with primary antiphospholipid syndrome which this coexisting is rarely seen in the literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The antiphospholipid syndrome involves long-term persistence of serum antiphospholipid antibodies and hypercoagulability manifested by venous or arterial thrombosis, recurrent pregnancy loss or thrombocytopenia.
📊
Key Findings & Data:Two forms have been described: the “primary syndrome” where there is no evidence of an underlying disease, and the “secondary syndrome”, mainly in the setting of systemic lupus eryhematosus.
💡
Conclusion & Impact:Herein we present a case of non-cirrhotic portal hypertension associated with primary antiphospholipid syndrome which this coexisting is rarely seen in the literature.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The antiphospholipid syndrome involves long-term persistence of serum antiphospholipid antibodies and hypercoagulability manifested by venous or arterial thrombosis, recurrent pregnancy loss or thrombocytopenia. Two forms have been described: the “primary syndrome” where there is no evidence of an underlying disease, and the “secondary syndrome”, mainly in the setting of systemic lupus eryhematosus. Classic features of antiphospholipid syndrome include cutaneous signs, such as livedo reticularis, splinter hemorrhages, superficial thrombophlebitis, and leg ulcers; venous thrombotic events, such as cerebral or retinal vein thrombosis; arterial thrombotic events, such as transient attacks or ischemic infarcts, recurrent spontaneous early-term abortions, and thrombocytopenia. Also various hepatic manifestations have been reported with antiphospholipid syndrome in literature, including Budd-Chiari syndrome, hepatic-veno-occlusive disease and occlusion of small hepatic veins, nodular regenerative hyperplasia and portal hypertension. Herein we present a case of non-cirrhotic portal hypertension associated with primary antiphospholipid syndrome which this coexisting is rarely seen in the literature.

Özet

Antifosfolipid sendrom, serumda uzun süre antifosfolipid antikorların varlığı, venöz ya da arteriyel trombozlar, tekrarlayıcı gebelik kayıpları veya trombositopeniyle karakterize sistemik otoimmün bir hastalıktır. İki formu tanımlanmıştır: başka hiç bir hastalığın eşlik etmediği birincil antifosfolipid sendrom ve genellikle sistemik lupus eritematozus gibi başka bir hastalığa eşlik eden ikincil antifosfolipid sendrom. Klasik özellikleri livedo retikularis, splinter hemorajiler, yüzeysel tromboflebit ve bacak ülserleri gibi deri bulguları; serebral, retinal ven trombozu gibi venöz trombotik olaylar; geçici iskemik atak ya da iskemik infarktlar gibi arteriyel trombotik olaylar, tekrarlayıcı erken-term spontan düşükler ve trombositopenidir. Budd-Chiari sendromu, hepatik veno-okluzif hastalık, küçük hepatik venlerin oklüzyonu, nodüler rejeneratif hiperplazi ve portal hipertansiyon gibi çeşitli karaciğer hastalıkları da antifosfolipid sendromu birlikteliğiyle literatürde bildirilmiştir. Biz de burada literatürde oldukça nadir görülen bir birliktelik olan primer antifosfolipid sendromuyla ilişkili non-sirotik portal hipertansiyon olgusu sunuyoruz.

🔖

Cite This Article

BES, C., GÜLTÜRK, E., NAMAL, E., PAKSOY, F., GÖKÇEN, D. G., BORLU, F., ULAŞ, T. (2022). A rare cause of non-cirrhotic portal hypertension: Primary antiphospholipid syndrome. Adnan Menderes Üniversitesi Tıp Fakültesi Dergisi, Cilt: 12 - Sayı: 3, 41–43. https://ajindex.com/articles/428925

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010;376:1498-509
  2. Park KW. Antiphosholipid syndrome. Int Anesthesiol Clin 2004;42:45-57
  3. Henderson JM, Barnes DS, Geisinger MA. Portal hypertension. Curr Probl Surg 1998;35:379-452
  4. Takahaski C, Kumagai S, Tsubata R, et al. Portal hypertension associated with anticardiolipin antibodies in a case of systemic lupus erythematosus. Lupus 1995;4:232-5
  5. Lee HJ, Park JW, Chang JC. Mesenteric and portal venous obstruction associated with primary antiphospholipid antibody syndrome. J Gastroenterol Hepatol 1997;12:822-6
  6. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346:752-63
  7. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999; 353(9161):1348-53. 8) de Groot PG, Derksen RH: Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost 2005;3:1854-60
  8. Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost 1995;74:1597-603
  9. Mackworth-Young CG. Antiphospholipid syndrome: multiple mechanisms. Clin Exp Immunol 2004;136:393-401
  10. Bayraktar Y, Tanaci N, Egesel T, Gököz A, Balkanci F. Antiphospholipid syndrome presenting as portopulmonary hypertension. J Clin Gastroenterol 2001;32:359-61
  11. Uthman I, Khamashta M. The abdominal manifestations of the antiphospholipid syndrome. Rheumatology (Oxford) 2007;46:1641-7.